Emerging in the arena of excess body fat management, retatrutide is a distinct strategy. Unlike many available medications, retatrutide operates as a dual agonist, at once targeting both glucagon-like peptide-1 (GLP-1) and glucose-responsive insulinotropic polypeptide (GIP) binding sites. The simultaneous engagement promotes multiple advantageous e